United Therapeutics Corp (UTHR) Financials

Key financial figures for United Therapeutics Corp (Q3 2026).

United Therapeutics Corporation reported revenue of $832.5 million for Q3 FY2026, up 4.1% from the same period a year earlier. Net income was $258.6 million, or $5.71 per share. Operating margin came to 36.97%, against 48.69% a year earlier. Free cash flow for the period was $125.8 million. Across the last 5 reported quarters, quarterly revenue has risen from $799.5 million in Q3 FY2025 to $832.5 million in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for United Therapeutics Corporation are on the SentiSense financials page.

Revenue
$833M
Net Income
$259M
EPS
$6.06
Total Assets
$7.0B
Operating Cash Flow
$307M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q3 FY2026$833M$259M$5.7136.97%$126M
Q2 FY2026$783M$333M$7.2742.23%$206M
Q1 FY2026$782M$275M$5.8241.69%$363M
Q4 FY2025$790M$364M$7.6645.24%$173M
Q3 FY2025$800M$339M$7.1648.69%$352M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$3.2B$1.3B$27.8647.67%$1.0B
FY2024$2.9B$1.2B$24.6447.86%$1.1B
FY2023$2.3B$985M$19.8150.91%$748M

Frequently asked questions

What was United Therapeutics Corporation's revenue last quarter?

United Therapeutics Corporation reported revenue of $832.5 million for Q3 FY2026, up 4.1% from the same period a year earlier.

Is United Therapeutics Corporation profitable?

Yes. United Therapeutics Corporation reported net income of $258.6 million for Q3 FY2026, a net margin of 31.06% on revenue.

How has United Therapeutics Corporation's margin trended?

Operating margin was 36.97% in Q3 FY2026, compared with 48.69% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.

How much free cash flow did United Therapeutics Corporation generate?

United Therapeutics Corporation generated free cash flow of $125.8 million in Q3 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for United Therapeutics Corp on SentiSense, with up to forty quarters and twenty fiscal years of history.